Mesoblast gets FDA nod for new potency assay to release Ryoncil batchesSep 23Regulatory decisionMesoblast, Ltd.
Mesoblast reports FY2026 revenue of $120.3 million, driven by Ryoncil launchAug 27Clinical readoutMesoblast, Ltd.
Mesoblast finishes dosing in Phase 3 trial of rexlemestrocel-L for chronic low back painAug 17Clinical readoutMesoblast, Ltd.
Mesoblast reports $36M quarterly Ryoncil revenue, $115M for first full yearJul 30Clinical readoutMesoblast, Ltd.
Mesoblast CEO Itescu exercises options, boosting stake to over 80.8 million sharesJul 20PeopleMesoblast, Ltd.
Mesoblast enrolls 300th patient in Phase 3 back pain trial of rexlemestrocel-LJul 14Clinical readoutMesoblast, Ltd.
Mesoblast gets BLA filing number for rexlemestrocel-L in LVAD patientsJun 30PartnershipMesoblast, Ltd.
Sign in